Last reviewed · How we verify
CA125 guided strategy
CA125 guided strategy uses serial measurement of the tumor marker CA125 to inform treatment decisions and monitoring in ovarian cancer patients.
CA125 guided strategy uses serial measurement of the tumor marker CA125 to inform treatment decisions and monitoring in ovarian cancer patients. Used for Ovarian cancer treatment monitoring and management.
At a glance
| Generic name | CA125 guided strategy |
|---|---|
| Also known as | Loop diuretic (Furosemide) dosage in CA125 ≤35 U/ml patients, Loop diuretic dosage (Furosemide) in CA125 >35 U/ml patients |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is a clinical management strategy rather than a drug itself, wherein CA125 (cancer antigen 125) levels are monitored during and after treatment to guide therapeutic decisions, assess treatment response, and detect recurrence. The approach aims to optimize chemotherapy timing and intensity based on CA125 kinetics, potentially improving outcomes while minimizing unnecessary treatment exposure.
Approved indications
- Ovarian cancer treatment monitoring and management
Common side effects
Key clinical trials
- Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF) (PHASE4)
- Carbohydrate Antigen 125-guided Therapy in Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: